TL;DR
Revolution Medicines' daraxonrasib nearly doubled median survival in pancreatic cancer versus chemotherapy — the largest gain in a decade, and oncologists are calling it a landmark.
MSM Perspective
Reuters Health covers it as a pipeline story; STAT News has the specialist reaction but most general outlets have missed the historical scale of the improvement.
X Perspective
Oncologists on X are describing this as a generational shift; the KRAS-undruggable framing they've held for twenty years is now wrong.
The median survival for patients with previously treated metastatic pancreatic cancer, in the largest clinical trial ever run for that specific population, was 6.7 months on chemotherapy. On daraxonrasib, it was 13.2 months. [1]
That is not a marginal improvement in one of oncology's most resistant cancers. It is the largest median overall survival gain in second-line pancreatic cancer in a decade. The hazard ratio was 0.40 — a 60% reduction in the risk of death.
Oncologists who spend their careers in this disease are calling it a landmark. The general press is treating it as a pipeline story. Those are not the same thing.
The KRAS Problem, Solved
Pancreatic ductal adenocarcinoma — PDAC — is driven by mutations in the RAS family of proteins in more than 90% of cases. For decades, that protein family was considered undruggable: its structure offered no obvious pocket for a small molecule to bind, and every attempt to target it directly failed. The oncology field built its PDAC treatment protocols around that assumption. The result is a disease with a five-year survival rate below 13%.
Daraxonrasib, developed by Revolution Medicines, is a RAS(ON) inhibitor — it binds the active form of the RAS protein directly, a mechanism that previous generations of targeted therapy could not achieve. The Phase 3 RASolute 302 trial enrolled patients with metastatic PDAC harboring a range of RAS variants, including G12D, G12V, and G12R mutations, as well as some patients without an identified tumor RAS mutation. [2]
The drug is taken orally, once daily. The comparator was investigator's choice of standard chemotherapy delivered intravenously. A daily pill outperforming IV chemotherapy by that margin, in that disease, is not a pipeline story. It is a structural change to what the field believes is possible.
The FDA's May Decision
On May 1, 2026, the FDA announced that Revolution Medicines could proceed with an expanded access treatment protocol for daraxonrasib. [3] Expanded access — sometimes called compassionate use — allows patients who do not qualify for a clinical trial, or who cannot access the drug through trial enrollment, to receive treatment while a New Drug Application is under review.
This is consequential in practical terms. Pancreatic cancer progresses quickly. The time between diagnosis and death, for patients without treatment options, is measured in months. The FDA's expanded access decision means that patients who match the trial's criteria — previously treated metastatic PDAC, RAS mutation-eligible — can now begin to access the drug before formal approval.
Revolution Medicines intends to submit data to global regulatory authorities, including a New Drug Application to the FDA, under a Commissioner's National Priority Voucher designation intended to accelerate review. [4] A parallel Phase 3 trial — RASolute 303 — has begun enrolling patients with previously untreated metastatic PDAC, testing daraxonrasib in the first-line setting. That trial will take years. The second-line data is what clinicians have now.
What the Specialists Are Saying
On X, the oncology accounts that track this disease reacted to the RASolute 302 results in April with language that general-audience coverage has not matched. Dr. Jason Williams, writing about the trial results, described KRAS as having been "called undruggable for decades" and the RASolute 302 data as showing daraxonrasib "nearly doubling survival in metastatic pancreatic cancer versus chemotherapy." [5] Paolo Tarantino, an oncologist, posted that the results were "amazing news" — language that is, in the context of pancreatic cancer, extraordinarily restrained.
The gap between specialist discourse and general coverage is the paper's story this week. The NEJM published Phase 1/2 data from the daraxonrasib program earlier in May, providing the mechanistic and early-trial foundation for the Phase 3 findings. [6] The FDA expanded access decision followed. The specialist community had already processed the trial results from their April announcement. The public conversation has not caught up.
For a disease that has resisted meaningful improvement for the length of most medical careers, 13.2 months versus 6.7 months is not a footnote. It is a new reference point. Everything that comes after it will be measured against it.
-- KENJI NAKAMURA, Tokyo